openPR Logo
Press release

Krabbe Disease Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | AlaMab Therapeutics, Zentalis Pharmaceuticals, Isofol Medical, Merck, Eisai Co Ltd, Jiangsu Hengrui M

01-13-2025 02:35 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Krabbe Disease Pipeline Insights 2024

Krabbe Disease Pipeline Insights 2024

Krabbe Disease Pipeline constitutes 8+ key companies continuously working towards developing 8+ Krabbe Disease treatment therapies, analyzes DelveInsight.

Krabbe Disease Overview:

Krabbe disease encompasses a range of conditions, from infantile-onset disease (characterized by symptoms such as extreme irritability, spasticity, and developmental delay before 12 months of age) to later-onset disease (where symptoms appear after 12 months, potentially as late as the seventh decade of life). Historically, 85%-90% of symptomatic individuals diagnosed through enzyme activity alone have had infantile-onset Krabbe disease, with 10%-15% having later-onset. However, newborn screening (NBS) has indicated that the prevalence of later-onset Krabbe disease may be higher than previously believed. Infantile-onset Krabbe disease typically involves normal development initially, followed by rapid and severe neurological decline, with an average life expectancy of 24 months (ranging from 8 months to 9 years). Later-onset Krabbe disease presents more variably and its progression is less predictable.

Request for a detailed insights report on Krabbe Disease pipeline insights @ https://www.delveinsight.com/report-store/krabbe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Krabbe Disease Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Krabbe Disease Therapeutics Market.

Key Takeaways from the Krabbe Disease Pipeline Report

DelveInsight's Krabbe Disease pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Krabbe Disease treatment.
In January 2025, The FDA awarded breakthrough therapy designation (BTD) to GSK5764227 (GSK'227) for treating adult patients with relapsed or refractory Krabbe Disease who have experienced disease progression after receiving at least two previous treatment regimens.
Key Krabbe Disease companies such as Forge Biologics, Passage Bio, Sanbio, Polaryx, Gain Therapeutics, and others are evaluating new drugs for Krabbe Disease to improve the treatment landscape.
Promising Krabbe Disease pipeline therapies in various stages of development include FBX-101, PBKR03, and others.

Krabbe Disease Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Krabbe Disease Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Krabbe Disease treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Krabbe Disease market.

Download our free sample page report on Krabbe Disease pipeline insights @ https://www.delveinsight.com/sample-request/krabbe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Krabbe Disease Emerging Drugs

FBX-101: Forge Biologics
PBKR03: Passage Bio

Krabbe Disease Companies

There are around eight key companies developing therapies for Krabbe Disease. Among them, Passage Bio has drug candidates for Krabbe Disease in the most advanced stage, specifically Phase I/II.

DelveInsight's report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Krabbe Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Krabbe Disease Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Krabbe Disease Therapies and Key Companies: Krabbe Disease Clinical Trials and advancements @ https://www.delveinsight.com/report-store/krabbe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Krabbe Disease Pipeline Therapeutic Assessment
• Krabbe Disease Assessment by Product Type
• Krabbe Disease By Stage
• Krabbe Disease Assessment by Route of Administration
• Krabbe Disease Assessment by Molecule Type

Download Krabbe Disease Sample report to know in detail about the Krabbe Disease treatment market @ Krabbe Disease Therapeutic Assessment @ https://www.delveinsight.com/sample-request/krabbe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Krabbe Disease Current Treatment Patterns
4. Krabbe Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Krabbe Disease Late-Stage Products (Phase-III)
7. Krabbe Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Krabbe Disease Discontinued Products
13. Krabbe Disease Product Profiles
14. Krabbe Disease Key Companies
15. Krabbe Disease Key Products
16. Dormant and Discontinued Products
17. Krabbe Disease Unmet Needs
18. Krabbe Disease Future Perspectives
19. Krabbe Disease Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Krabbe Disease Pipeline Reports Offerings: https://www.delveinsight.com/report-store/krabbe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Krabbe Disease Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | AlaMab Therapeutics, Zentalis Pharmaceuticals, Isofol Medical, Merck, Eisai Co Ltd, Jiangsu Hengrui M here

News-ID: 3812832 • Views:

More Releases from DelveInsight Business Research LLP

Crohn's Disease Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (Zeria Pharmaceutical), Gilead S
Crohn's Disease Market Report 2034: Epidemiology Data, Pipeline Therapies, Lates …
DelveInsight's "Crohn's Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Crohn's Disease, historical and forecasted epidemiology as well as the Crohn's Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Crohn's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Crohn's Disease Market Forecast @ https://www.delveinsight.com/report-store/crohns-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr Some
Complicated Urinary Tract Infections Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, Allecra Therapeutics, Nabriva Therapeutics AG, MerLi
Complicated Urinary Tract Infections Market Report 2034: Epidemiology Data, Pipe …
DelveInsight's "Complicated Urinary Tract Infections Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Complicated Urinary Tract Infections, historical and forecasted epidemiology as well as the Complicated Urinary Tract Infections market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Complicated Urinary Tract Infections market outlook, drug uptake, treatment scenario and epidemiology trends, Click
Myasthenia Gravis Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Viela Bio, UCB Pharma, Momenta Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Hoffmann-La Roche, Alexio
Myasthenia Gravis Market Report 2034: Epidemiology Data, Pipeline Therapies, Lat …
DelveInsight's "Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Myasthenia Gravis, historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Myasthenia Gravis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myasthenia Gravis Market Forecast @ https://www.delveinsight.com/report-store/myasthenia-gravis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr Some of the
Gastroesophageal Reflux Disease Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Cinclus Pharma, Onconic Therapeutics, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno
Gastroesophageal Reflux Disease Market Report 2034: Epidemiology Data, Pipeline …
DelveInsight's "Gastroesophageal Reflux Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Gastroesophageal Reflux Disease, historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Gastroesophageal Reflux Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroesophageal Reflux Disease

All 5 Releases


More Releases for Krabbe

Krabbe Disease Drugs Market Global Strategies and Insight driven transformation …
Krabbe Disease Drugs Market research report is a professional and an in-depth study available on the market size, share, growth, trends, in addition to industry evaluation. Krabbe Disease Drugs Market report provides a thorough analysis and competitive analysis by region and added main information like a manufacturing process, raw material and equipment suppliers, various manufacturing associated costs, revenue, historical and futuristic cost, demand and supply data. Moreover, the study presents a
Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics - Pipeline Analysis | …
Globoid cell leukodystrophy, also known as Krabbe disease, is a genetic disorder which is characterized by decreased production of galactocerebrosidase. The symptoms observed during Krabbe disease are fever, vomiting, loss of head control, irritability and excessive crying, seizures, poor coordination of movement or stiffness, muscle spasms, changes in muscle tone, deterioration of motor function, difficulty walking and muscle weakness. Download the sample report @ https://www.pharmaproff.com/request-sample/1133 There is no cure for Krabbe
Krabbe Disease Treatment Market - Global Industry Trends,Size, Applications and …
Krabbe disease is a rare inherited genetic disorder that affects the nervous system. It is usually caused by the deficiency of the galactosylceramidase (GLC) enzyme. The disease is inherited in an autosomal recessive pattern. global krabbe disease treatment market to grow at a CAGR of 7.24% during the period 2018-2022. Get Sample@ https://www.researchbeam.com/global-krabbe-disease-treatment-2018-2022-market/request-sample Covered in this report The report covers the present scenario and the growth prospects of the global krabbe disease
Krabbe Disease Treatment Market to Observe Strong Development by 2025
Krabbe disease treatment is a rare autosomal recessive lysosomal related disorder affecting the white matter of the peripheral and central nervous system. It is a genetic disorder, which is passed down one generation to another in families. It is also called globoid cell leukodystrophy disease. Persons suffering from Krabbe disease treatment are unable to produce sufficient amount of galactosylceramidase, which is essential for myelin production and breaks down several important
Krabbe Disease Treatment Market Flourishes Key Players Share, Revenue, Demand an …
The Global Krabbe Disease Treatment Market report explores the key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market. The Krabbe Disease Treatment Market has been segmented on the basis of types of treatments which comprises of anticonvulsant medication, physical therapy, muscle relaxer drugs, bone marrow transplantation and others. On the basis of end users the market is
Global Clinical Trials Review for Globoid Cell Leukodystrophy (Krabbe Disease), …
"The Report Globoid Cell Leukodystrophy (Krabbe Disease) Global Clinical Trials Review, H2, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" ​Globoid Cell Leukodystrophy (Krabbe Disease) Global Clinical Trials Review, H2, 2017 Summary GlobalDatas clinical trial report, Globoid Cell Leukodystrophy (Krabbe Disease) Global Clinical Trials Review, H2, 2017" provides an overview of Globoid Cell Leukodystrophy (Krabbe Disease) clinical trials scenario. Get Sample copy of this